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Abstract: The extraction, fractionation and HIV-1 inhibition potential of polysaccharides 
extracted from three species of marine sponges, Erylus discophorus, Cliona celata and 
Stelletta sp., collected in the Northeastern Atlantic, is presented in this work. The anti-HIV 
activity of 23 polysaccharide pellets and three crude extracts was tested. Crude extracts 
prepared from Erylus discophorus specimens were all highly active against HIV-1 (90 to 
95% inhibition). Cliona celata pellets showed low polysaccharide content (bellow 38.5%) 
and almost no anti-HIV activity (<10% inhibition). Stelletta sp. pellets, although quite rich 
in polysaccharide (up to 97.3%), showed only modest bioactivity (<36% HIV-1 inhibition). 
Erylus discophorus pellets were among the richest in terms of polysaccharide content (up 
to 98%) and the most active against HIV-1 (up to 95% inhibition). Chromatographic 
fractionation of the polysaccharide pellet obtained from a specimen of Erylus discophorus 
(B161) yielded only modestly active fractions. However, we could infer that the active 
molecule is most probably a high molecular weight sulfated polysaccharide (>2000 kDa), 
whose mechanism is possibly preventing viral attachment and entry (fusion inhibitor). 
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1. Introduction 
Sponges are filter feeding benthonic animals that have survived until present almost 
morphologically unaltered since the Superior Cambrian (509 million years ago) [1]. They represent the 
simplest multicellular life form present nowadays in our planet, similar, in evolutionary terms, to 
primordial multicellular organisms [2]. Sponges are the most primitive animals living today and, for 
that, they are considered living fossils [3]. These animals are so peculiar that, in the Metazoa kingdom, 
a whole phylum is dedicated to them—Phylum Porifera [4]. Currently, there are 8365 known sponge 
species [5] and, of these, around 98% live in marine habitats [1]. They attach to the marine substratum 
in many different depths (from intertidal zones to abyssal pits), temperatures, salinities and light 
conditions [6] and exist in a multitude of colors and shapes.  
Natural products have long been used in food, fragrances, pigments, insecticides, drugs,  
cosmetics, etc. The pioneering work of Bergmann and collaborators in the 50s, giving the first insight 
into the area of marine natural products, resulted in the discovery of nucleoside analogues synthesized 
by marine sponges [7,8]. These were isolated for the first time in the sponge Cryptotethia crypta and, 
years later, served as an inspiration for the synthesis of the first and best known antiretroviral 
compound: zidovudine or AZT [9].  
In the late 80s, the National Cancer Institute set up a large-scale screening program, with a wide 
variety of marine invertebrates, terrestrial plants and microorganisms being tested for their anti-HIV 
activity [10,11]. In the following years, around 40.000 organic and aqueous extracts were tested and, 
surprisingly, around 15% demonstrated at least some HIV inhibitory effect [11]. Many of these 
extracts exhibited bioactivity profiles similar to sulfated dextran or other high molecular weight 
sulfated polysaccharides extracted from sponges and algae [10]. Since then, studies on the discovery 
and isolation of new natural substances, with unique structures, displaying anti-HIV activities, have 
proliferated, with compounds from many different origins being reported—terrestrial plants, algae, 
microorganisms (bacteria, fungi, microalgae), sponges, echinoderms, tunicates, corals, crustaceans, 
molluscs, etc.—and also covering a wide range of chemical varieties—peptides and proteins [12,13], 
glycoproteins [14], polysaccharides (anionic, sulfated), flavonoids, coumarines, terpenoids, 
alkaloids [15], polyphenols [16], sterols, sulfolipids, lactones, among others [9,11,17–19]. Among all 
marine organisms, sponges are the most prolific in novel compounds, with more than 200 new 
metabolites being reported every year, presenting biological activities as diverse as antibiotic, 
antitumor, antiviral and anti-inflammatory [20].  
Despite the intense research effort by academic and corporate institutions, very few natural products 
with real potential have been identified or developed [21]. At present, there are 25 chemical 
compounds formally approved by the Food and Drug Administration for the treatment of human 
immunodeficiency virus infection [22], none of them is of natural origin. 
Polysaccharides play a crucial role in cell interaction and recognition processes, participate in 
structural events and are associated with cell differentiation and/or proliferation processes [23,24]. 
Sulfated polysaccharides with unique structures are also present in several marine sponge species, 
taking part in cell adhesion and recognition processes [2,24–26]. Several extraction and 
characterization methods are known since 1947, as well as their anti-clotting and immunological 
properties [23]. Polysaccharides have also long been known for their antiviral properties [10]. Since 
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1988, the activity spectrum of the sulfated polysaccharides has been shown to extend to various 
enveloped viruses [27]. Against HIV, they possibly act by blocking the viral gp120 adsorption to the 
lymphocytic cell [28,29]. Although these polyanionic molecules exhibit a broad spectrum antiviral 
activity together with low viral resistance induction, their low specificity pharmacological properties 
lead to a weak anti-HIV activity in vivo [30].  
In the marine environment, sulfated polysaccharides extracted from algae have been intensively 
studied for their antiretroviral activities [27,31–37] but only few examples regarding the antiviral 
activities of glycosidic molecules extracted from marine sponges have been reported in the 
literature [10,14,38,39]. In this work, we report preliminary assays on the anti-HIV activity of extracts 
from marine sponges collected in the Western Portuguese Coast, Northeastern Atlantic. Stelletta sp. 
(former Myriastra sp.), Cliona celata and Erylus discophorus anti-HIV surveys yielded a small activity 
for the first species, the second species produced almost no activity and only  
E. discophorus extracts presented an extremely potent inhibitory effect on HIV-1. Since 
polysaccharides can be responsible for this type of activity, we tested several polysaccharide 
fractionation methods and their anti-HIV potential. 
2. Results and Discussion 
2.1. Extraction Methods 
Four different polysaccharide extraction methods were applied to six sponge samples: B22 
(Stelletta sp.), B33 and B124 (Cliona celata) and B161, B206 and B294 (Erylus discophorus), thus 
providing us with 24 polysaccharide pellets (these pellets will be further addressed in the format 
specimen(extraction method); example: B33(II) would refer to the polysaccharide pellet extracted from 
specimen B33 according to extraction method II). B358 and B437 were only used in crude extract 
preparation; no polysaccharide extraction was performed with these samples.  
Polysaccharide pellets were weighed once completely dry (Table 1), dissolved in water and assayed 
with toluidine blue for sulfated polysaccharide concentration (Table 2). Since there can be  
co-precipitation of other molecules in the pellet, percentage of sulfated polysaccharides effectively 
extracted in each pellet was calculated (Figure 1).  
As can be seen in Tables 1 and 2, polysaccharide concentration varies largely among sponge 
samples and extraction methods. The polysaccharide content constitutes 0.02 to 0.39% of the total 
sponge dry weight for Cliona celata specimens, 0.66 to 22.3% for Erylus discophorus specimens and 
0.67 to 4.2% for Stelletta sp. Several authors have reported variable contents of sulfated 
polysaccharides in marine sponges: Zierer et al. reported that, in four different marine sponge species, 
approximately 1% of the sponge dry weight consists of acidic polysaccharides [40,41]; Vilanova et al., 
working with four different species of Chondrilla sp., reported a polysaccharide content of up to 3% of 
the sponge dry weight [42]. These results are probably a reflection of the high variability of 
polysaccharide content between different sponge species, not only in quantity but also in the type of 
polysaccharides, as reported by Vilanova et al. [42].  
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Table 1. Dry weight (mg) of the final polysaccharide pellets obtained per gram of dry 
sponge tissue. 
Method 
Sample I II III IV 
B22 98.09 20.87 35.47 24.07 
B33 9.43 13.80 5.46 0.52 
B124 13.37 8.39 6.22 4.72 
B161 299.20 84.27 89.44 35.59 
B206 139.46 28.36 81.08 20.80 
B294 135.15 32.27 52.02 20.76 
Table 2. Sulfated polysaccharide quantification as determined by the toluidine blue assay 
(mg of sulfated polysaccharide per gram of dry sponge tissue). 
Method 
Sample I II III IV 
B22 42.11 6.67 33.27 23.41 
B33 2.36 2.28 1.89 0.20 
B124 3.86 1.29 2.09 1.49 
B161 223.34 19.46 56.84 34.98 
B206 55.72 7.90 59.72 13.72 
B294 60.57 6.59 38.76 14.03 
Figure 1. Percentage of sulfated polysaccharides in the final pellets ((polysaccharide mass 
determined by toluidine blue/total pellet weight) × 100).  
 
Looking at the results obtained for Cliona celata (B33 and B124), one can see that, regardless of 
extraction method, it is not only the species with lowest polysaccharide pellets (Table 1), ranging from 
0.52 mg to 13.80 mg of polysaccharide pellet per g of dry sponge weight, but it also gave rise to the 
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least rich polysaccharide pellets (Figure 1), with only 15.4 to 38.5% of the pellet being effectively 
composed of polysaccharides. Erylus discophorus seems to be the sponge species with highest content 
in terms of polysaccharide, with pellets weighing 20.80 to 299.20 mg per gram of sponge dry weight. 
Erylus discophorus specimens also provided some of the richest pellets in terms of polysaccharide 
percentage, with pellet B161(IV) being almost exclusively composed of polysaccharides (98.3%). 
Regarding Stelletta sp., it is difficult to extract general conclusions since only one specimen was 
analyzed. Even so, we can say that sample B22 would be a moderately rich sponge in terms of 
polysaccharide content and that extraction methods III and IV were particularly efficient, providing us 
with two pellets of very high polysaccharide yield (93.8 and 97.3% for B22(III) and B22(IV), 
respectively). To our knowledge, there are no previous studies on the polysaccharide content of these 
species, which does not allow us to further generalize our observations.  
As can be seen in Figure 1, the least efficient method, in terms of polysaccharide extraction, is 
method II, followed by method I. Since the latter consists of a simple ethanolic precipitation, there is 
most likely co-precipitation of other cellular components such as proteins and nucleic acids, and thus 
low yields of polysaccharide concentration in the recovered pellets. Although method II seems to be 
somewhat more specific than method I, including an extraction step with CPC, polysaccharide content 
in method II pellets is consistently lower in all samples. One should take into account that, as 
previously reported by Beutler et al., (1) the extraction methodology used in method I produces quite 
variable yields of polysaccharides and (2) the complexity of the matrix may influence the accuracy of 
the colorimetric determination using toluidine blue.  
Extraction methods III and IV were the most efficient, with a content of up to 98.3% 
polysaccharides in the pellet obtained from sample B161 using method IV. Since extraction 
methods III and IV are more complex, involving further fractionation steps, these results are not 
surprising. The fractionation steps of proteolytic digestion with papain and nucleic acid degradation 
with DNase that comprise method IV, clearly made a difference when regarding polysaccharide purity, 
giving rise to two of the richest pellets in terms of polysaccharide content: B22(IV) and B161(IV), 
with a content of 97.3% and 98.3%, respectively. Thus, method IV would obviously be the preferred 
method for polysaccharide extraction in these samples.  
2.2. HIV-1 Inhibition Activity 
All polysaccharide pellets (except for B33(IV) which was lost) were dissolved in double distilled 
water, in a 50 mg/mL proportion, and tested for their anti-HIV properties. Crude extracts from B161 
and two other Erylus discophorus samples, B358 and B437, were also assayed for anti-HIV activity. 
All samples were checked for cell viability, discarded in case of massive cell death and assayed again. 
P24 concentrations were extrapolated in a previously constructed p24 standard titration curve and 
inhibition percentage was calculated after setting the positive control as 0% inhibition and negative 
control as 100% inhibition. 
As can be seen in Figure 2, all crude extracts prepared from Erylus discophorus specimens 
presented an extremely potent inhibitory activity (90 to 95% HIV-1 inhibition). Regarding 
polysaccharide pellets, although pellets obtained from sample B22 were richer in  
terms of polysaccharide percentage, they present only moderate HIV inhibition as opposed to 
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Erylus discophorus specimens, in which almost all polysaccharide pellets, regardless of specimen or 
extraction method, presented an HIV inhibition percentage of over 50%, exceptions being B161(III) 
and B294(IV). This observation points to the presence of polysaccharides with different structural 
features in marine sponges belonging to Erylus discophorus species. Indeed, there are several  
studies reporting the direct correlation of anti-HIV activity of sulfated polysaccharides with specific 
structural parameters [33], such as: increasing molecular weight and degree of sulfation, 
homopolymerization [27,35], charge density [43] and nature of counter-ion [44]. 
Figure 2. HIV-1 inhibition activity of crude extracts and polysaccharide pellets prepared 
from marine sponge samples belonging to three different species: Erylus discophorus 
(B161, B358, B437, B206 and B294), Stelletta sp. (B22) and Cliona celata (B33 and 
B124); CE: crude extract; I, II, III and IV refer to polysaccharide extraction method. 
 
Sponge sample B161 originated three of the most HIV-inhibitory pellets: B161(I), B161(II) and 
B161(IV) with 80, 95 and 86% inhibition percentage, respectively. Given that the B161(IV) pellet is 
almost exclusively constituted of sulfated polysaccharides (98.3%), they are most likely responsible 
for the observed HIV-inhibitory activity. Although the B161(II) pellet showed the highest inhibition 
percentage, its polysaccharide content is quite low, probably due to few fractionation steps in 
extraction method II. 
Polysaccharide pellets obtained from Cliona celata specimens presented the lowest inhibitory effect 
(lower than 10%, except for B124(III)), which can be correlated with low polysaccharide content.  
B161(CE) test for the drug susceptibility assay performed in pre-infected cells showed no inhibitory 
effect of the tested sample, implying that the molecule in study affects infection probably by 
preventing HIV attachment and entry into the lymphocytic cell, working as a fusion inhibitor. These 
observations are also in accordance with previous studies showing the involvement of sulfated 
polysaccharides in blocking early events of viral replication [27,31,43,45,46]. 
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2.3. Bioassay Guided Fractionation 
B161 was chosen for further bioassay guided fractionation of the polysaccharide pellet due to 
several reasons: high available biomass, high inhibition activity against HIV and rich polysaccharide 
pellets. The polysaccharide pellet obtained from sponge sample B161 with extraction method IV, 
B161(IV), was dissolved in double distilled water and fractionated in a previously calibrated gel 
filtration chromatography column, resulting in the chromatogram presented in Figure 3. 
Figure 3. B161(IV) gel filtration chromatography in Sephacryl S-300 HR. 
 
Fractions corresponding to each of the two peaks observed were pooled and concentrated. 
Concentrated fractions were tested for HIV inhibition and activity remained exclusively in the first 
peak. Elution volume corresponding to maximum absorbance at 280 nm was around 45 mL. Elution 
volume of dextrane blue (2000 kDa molecular weight), as determined in the column calibration (results 
not shown), was around 52 mL. Thus, according to these data, the biologically active molecule has a 
very high molecular weight of over 2000 kDa. Previous studies on anti-HIV sulfated polysaccharides 
extracted from marine invertebrates are consistent, reporting molecular weights of 500 to 1000 kDa [10] 
and over 1500 kDa with high degree of sulfation [39].  
The fact that the active fraction absorbs at 280 nm may indicate the presence of proteic components. 
Whether these are contaminants or comprise an active glycoprotein or proteoglycan, remains 
unknown. Sponge proteoglycans, otherwise known as aggregation factors, are large molecules with 
approximate molecular weights ranging from 2 × 104 kDa to 1.4 × 106 kDa [26]. There are no previous 
records of anti-HIV proteoglycans in marine sponges but a few bioactive protein and glycoproteins 
have been reported [12,14].  
Although this chromatography was successful in giving us some insights into a few molecular 
characteristics, it did not constitute a good separation step, since there was massive bioactivity loss. 
Several other chromatographic separations were attempted, none with satisfactory results regarding 
fractionation and bioactivity maintenance. The huge loss of bioactivity observed can be due to several 
problems: (1) a concentration problem in chromatography fractions; (2) HIV-1 inhibition activity 
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results from the synergistic effect of more than one molecule, hence the activity loss when the sample 
is fractionated; (3) fractionation and consequent dilution results in loss of stability of the bioactive 
molecule; (4) bioactivity is merely due to a stereochemical hindrance effect of the bioactive molecule 
on the lymphocytic cell receptors, preventing HIV to attach and initiate subsequent infection events.  
3. Experimental Section 
3.1. Biological Material 
Samples were collected by scuba diving at Reserva Natural da Berlenga (Portuguese western coast, 
Northeastern Atlantic) in several missions (1998–2004) at depths of 4–10 m. Immediately after 
collection, a voucher sample was taken in ethanol 90% for identification and the remaining sample was 
frozen at −20 °C, transported to the laboratory in isothermal containers and stored at this temperature 
until required. 
All samples had an identification number. Table 3 summarizes sponge samples used in this study: 
five specimens of Erylus discophorus (B161, B206, B294, B358 and B437), two specimens of 
Cliona celata (B33, B124) and one specimen of Stelletta sp. (B22), all collected in Reserva Natural 
da Berlenga. 
Table 3. Sponge samples and species used in this study. 
Sample Species 
B161 
Erylus discophorus 
B358 
B437 
B206 
B294 
B22 Stelletta sp. 
B33 Cliona celata B124 
3.2. Crude Extract Preparation 
Around 65 g of tissue from each sponge specimen was cut into small pieces, ground and 
homogenized in double distilled water (10% w/v). The resulting homogenate was stirred for 30 min at 
4 °C, followed by centrifugation (15,300 g for 35 min at 4 °C). The pellet was discarded and the 
supernatant consisted of the crude extract (CE). 
3.3. Polysaccharide Extraction  
Four different procedures were used to extract polysaccharides from the biological material: 
Method I [10]—An equal volume of ethanol was added (ca. 650 mL) to the previously prepared 
crude extract. This ethanol suspension was left overnight at −20 °C. The precipitate was separated by 
centrifugation (3840 g for 60 min at 4 °C) and dried in an oven at 60 °C. 
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Method II [47]—The crude extract was heated at 37 °C in a water bath, together with a solution of 
5% (w/v) of cetylpyridinium chloride (CPC). The addition of one volume of the CPC solution, 
dropwise, to 5 volumes of the extract yielded a floccular precipitate. When all the solution had been 
added, the mixture was left for one more hour to ensure complete precipitation of the polysaccharides. 
These were separated by centrifugation (3840 g for 5 min at room temperature). The precipitate was 
dissolved in 2 M NaCl-ethanol (100:15, v/v) to convert the cetylpyridinium complexes into sodium 
salts (1 volume of this solution to 5 volumes of the aqueous extract). 
The polysaccharides were precipitated from this solution using 3 volumes of ethanol. The mixture 
was left in an ice bath for 1 h, prior to centrifugation (15,300 g for 35 min at room temperature). The 
pellet was again dissolved in double distilled water. The final precipitate formed after the addition of 
3 volumes of ethanol and incubation overnight at 4 °C. The precipitate, collected by centrifugation 
(15,300 g for 35 min at room temperature), was dried in an oven at 60 °C. 
Method III [48]—A piece of sponge was thawed and added to circa 10 volumes of acetone for 24 h 
at 4 °C, after which it was chopped into small pieces and dried in an oven at 60 °C. The dried tissue 
(10 g) was suspended in 300 mL of 0.1 M sodium acetate buffer (pH 5.0), containing 1 g of papain, 
5 mM cystein and 5 mM EDTA. This suspension was incubated at 60 °C for 24 h. After centrifugation 
(2460 g for 15 min at 10 °C), the polysaccharides present in the supernatant were precipitated with 
16 mL of a 10% (w/v) solution of cetylpyridinium chloride (CPC). The mixture was left for 24 h at 
room temperature, and centrifuged (2460 g for 15 min at room temperature). The precipitated 
polysaccharides were resuspended in 150 mL of 2 M NaCl-ethanol (100:15, v/v) and again precipitated 
with 300 mL ethanol 95%. After 24 h at 4 °C, the precipitate was collected by centrifugation and 
washed twice with 300 mL 80% ethanol and once with 95% ethanol. The final product was dried in an 
oven at 60 °C. 
Method IV [40]—A piece of sponge was thawed and added to circa 10 volumes of acetone for 24 h 
at 4 °C. After this time, it was chopped into small pieces and dried in an oven at 60 °C. The dried 
tissue (10 g) was suspended in 300 mL of 0.1 M sodium acetate buffer (pH 5.0), containing 1 g of 
papain, 5 mM cystein and 5 mM EDTA. This suspension was incubated at 60 °C for 24 h and 
centrifuged (2460 g for 15 min at 10 °C). The supernatant was heated at 100 °C for 10 min and cooled 
to room temperature. Then, it was incubated with 1060 U DNase I for 24 h at room temperature, with 
stiring. Centrifugation (24,000 g for 15 min at 10 °C) yielded a supernatant that was precipitated with 
37.5 mL of 10% (w/v) CPC. The mixture was left for 24 h at room temperature and centrifuged again 
(2460 g for 15 min at room temperature). The precipitated polysaccharides were resuspended in 
150 mL of 2 M NaCl-ethanol (100:15 v/v) and again precipitated with 300 mL ethanol 95%. After 24 h 
at 4 °C, the precipitate was collected by centrifugation and washed twice with 300 mL of 80% ethanol 
and once with 95% ethanol. The final product was dried in an oven at 60 °C. 
3.4. Quantification of Sulfated Polysaccharides 
Sulfated polysaccharides were quantified using the toluidine blue assay [10,49] and fucoidan as 
standard. Polysaccharide pellets obtained from each extraction were dissolved in double distilled water 
and diluted until polysaccharide concentration was in the range of the calibration curve and could be 
calculated by direct extrapolation. 200 µL aliquots of standard fucoidan solutions, in the range of 0 to 
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10 µg, and diluted samples were mixed with 1 mL of a 0.01 mg/mL solution of toluidine blue and, 
after 10 min, absorbance readings were taken at 620 nm. Polysaccharide determinations in both 
standards and samples were made in triplicate and median values were used for calculations.  
3.5. Chromatographic Fractionation 
Chromatographies were performed in a FPLC (Fast Protein Liquid Chromatography) system, 
coupled to a UV detector set at 280 nm and an automated fraction collector (Pharmacia Biotech). 
Sponge sample B161 was chosen for subsequent fractionation due to higher available biomass together 
with very active polysaccharide pellet. 
The final polysaccharide pellet obtained from sample B161 with extraction method IV, B161(IV), 
was dissolved in double distilled water in 50 mg/mL proportion. This solution was fractionated using 
gel filtration chromatography (Sephacryl S-300 High Resolution, Pharmacia Biotech), in a manually 
packed column of 140 mL bed volume. Sample (2 mL) was eluted with 100 mL of double distilled 
water, at a constant flow rate of 0.5 mL/min.  
Fractions corresponding to each chromatographic peak were pooled, concentrated (using 
ultrafiltration) and tested for HIV-1 inhibition activity. 
3.6. HIV-1 Inhibition Determination  
HIV-1 inhibition activity was determined using the in vitro HIV drug susceptibility assay [50], 
which measures the extent to which a drug inhibits HIV p24 antigen production by lymphocytic cells 
acutely infected with a viral isolate. The HIV-1 inoculum, NL4-3 strain, was produced by transfection 
of 293T lymphoblastic cells, using Fugene 6 (Roche) as the transfection agent. The viral supernatant 
was collected 48 h after transfection, aliquoted and kept at −20 °C until required. Viral infectivity, 
expressed in terms of 50% Tissue Culture Infectious Dose (TCID50), was determined prior to the drug 
susceptibility test, using a streamlined endpoint dilution assay that was analyzed by the Spearman-Karber 
statistical method [50]. Both infectivity and drug susceptibility assays were performed using Jurkat 
lymphocytic cell line. 
The drug susceptibility assay was performed in 96-well plates using 200,000 Jurkat cells per well, 
1000 TCID50 of the viral inoculum per million cells, 20 µL of sample (or sample buffer in the case of 
the positive control) and cell culture medium to 200 µL volume completion. Negative control 
consisted of non-infected cells and sample buffer. Prior to infection, cells were incubated with each 
sample for 1 h at 37 °C, after which the HIV inoculum was added. On day 4, cells were examined 
microscopically and 125 µL of cell suspension from each well was mixed, removed and discarded, 
followed by new addition of 20 µL of sample and 130 µL of growth medium. On day 7, HIV p24 
antigen concentration was determined using the INNOTEST HIV Antigen mAb kit (Innogenetics), 
according to the manufacturer’s instructions. For a preliminary insight into the viral inhibition 
mechanism, an assay was performed with pre-infected cells incubated with a previously known 
inhibitory sample. 
In parallel, all samples were checked for cell viability, serving as a control for the drug 
susceptibility assay, making sure all inhibitory effects would be due to the sample itself and not to cell 
death (implicating low or none viral replication). The cell viability assay replicated the drug 
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susceptibility assay but with no viral inoculum. On day 7, 20 µL of the cell proliferation reagent WST-1 
was added to each well, incubated for 30 min to 4 h and absorbance readings at 450 nm were taken, 
with a reference filter of 620 nm. 
4. Conclusions 
AIDS and HIV infection is one of the most worrying world epidemics nowadays, with 
consequences at political, social, economic, scientific and medical levels. Despite all efforts in fighting 
this disease, it does not show signs of slowing down [51]. There is an urge for new and more efficient 
drugs, able to overcome viral resistance, with lower side effects to the patient and the ability to provide 
total viral clearance. In this context, the scientific community has joined efforts in the research and 
development of novel compounds capable of permanently eradicating this disease. 
More than often, nature has served as inspiration or source for new molecules with extremely potent 
antiviral properties. With the rise and access to new submersion technologies, researchers have turned 
their attention to the marine environment in the quest for finding new promising bioactive compounds. 
Knowledge has been gained in unique ecosystems, extraordinary organisms with noteworthy 
adaptations and exclusive compounds demonstrating a wide range of biological and pharmacological 
properties. Marine sponges, in this matter, were revealed to be important sources of new substances 
and interesting research targets in biotechnology [52]. 
In this work, we have discovered and explored the extremely potent HIV-1 inhibitory activity 
present in the marine sponge Erylus discophorus. This bioactivity seems to be species-specific, in the 
matter that it is consistently found in all Erylus discophorus specimens. The molecule responsible for 
the anti-HIV activity is most probably a high molecular weight sulfated polysaccharide (over 
2000 kDa). Inhibition mechanism is expected to work at the viral entry, preventing HIV adsorption and 
fusion with the lymphocytic cell.  
Over the last 20 years of microbicide research, none of the 11 effectiveness trials of six candidate 
products have demonstrated meaningful protection against HIV infection [53]. Although the systemic 
applications of sulfated polysaccharides may have many drawbacks, their structure and mode of action 
indicate potential for topical uses to prevent virus infection [21]; they are able to block HIV without 
toxicity to the host cells, they are known to lead very slowly to virus drug resistance development and 
they show activity against HIV mutants that have become resistant to reverse transcriptase 
inhibitors [27]. Even if isolation of the bioactive compound is not feasible, the broad spectrum  
anti-HIV activity of the polysaccharide extracts from Erylus discophorus samples could be of use as a 
first antiviral barrier if applicable in vaginal gels or lubricants, should it prove to be non-toxic and 
effective in vivo. 
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